Drugs / ABCL575
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07108894 | Jul 2025 → Apr 2027 expected | — | AbCellera Biologics Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | AbCellera Biologics Inc. | Regulatory AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 abcellera.com ↗ |
| 2025-05-09 | AbCellera Biologics Inc. | Results AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting abcellera.com ↗
AbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in San Diego, California. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-27 | AbCellera Biologics Inc. | AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 abcellera.com ↗ |
| 2025-05-30 | AbCellera Biologics Inc. | AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 abcellera.com ↗ |
| 2025-05-09 | AbCellera Biologics Inc. | AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting abcellera.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABCL575 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07108894 ↗ |
| Route | Subcutaneous | “Healthy participants will receive a single dose of ABCL575 administered by subcutaneous (SC) injection” NCT07108894 ↗ |